Clinical Trial

Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2026 (before its estimated April 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-14.
Status change: Not Yet Recruiting → Recruiting 2026-02-02
Trial Details
NCT Number NCT07342868
Lead Sponsor Aligos Therapeutics
Conditions Chronic Hepaititis B Infections
Enrollment 16 participants
Start Date 2026-01-30
Primary Completion 2026-04-20 (estimated)
Study Completion 2026-05-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-04